Priority Lists
Protocol Posting of
Activations
Activation
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients with Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy
Study Coordinator(s) | David C. Smith, M.D. |
Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists, RTOG, CTSU |
Activation
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (12 Weeks vs 18 Weeks) as Adjuvant Therapy for Women With Node-Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study
Action Codes | ER |
Study Coordinator(s) | Silvana Martino, D.O. |
Participants | CTSU |
ACTIVATION Effective June 15, 2002
A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients, (A BMT Study)
Study Coordinator(s) | Mohamad A. Hussein, M.D., John D. Shaughnessy, Jr., Ph.D., James A. Waldron, M.D.,Ph.D., Jeffrey A. Zonder, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, Limited Institutions: BMT Members |
Closures
Permanent Closure
A Phase II Study of Observation in Favorable Low Grade Glioma and a Phase III Study of Radiation with or without PCV Chemotherapy in Unfavorable Low-Grade Glioma
Action Codes | NR |
Study Coordinator(s) | Geoffrey R. Barger, M.D., Keith J. Stelzer, M.D.,Ph.D. |
Participants | Members, Medical Oncologists, Pathologists, Radiation Oncologists, NCORP |
Closure Date | 2002-06-27 |
Amendments, Revisions, Memoranda
Memorandum
A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma
Participants | Members, NCORP, Surgeons, Pathologists |
Memorandum
A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera
Participants | Members, NCORP, Surgeons, Pathologists |
Memorandum
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma.
Study Coordinator(s) | Carolyn M. Johnston, M.D. |
Participants | Members, NCORP |
Memorandum
A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma.
Study Coordinator(s) | Amy D. Tiersten, M.D. |
Participants | NCORP, Members, Surgeons, Pathologists |
Memorandum
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
Study Coordinator(s) | Silvana Martino, D.O. |
Memorandum
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
Study Coordinator(s) | Stephen K. Williamson, M.D. |
Participants | Members, Surgeons, NCORP |
Revision #3
A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma
Study Coordinator(s) | Deborah T. Blumenthal, M.D., Alexander M. Spence, M.D., Keith J. Stelzer, M.D.,Ph.D., Andrew Edward Sloan, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, Radiation Oncologists |
Revision #5
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
Study Coordinator(s) | Quynh-Thu X. Le, M.D., Stephen K. Williamson, M.D., Janice Ryu, M.D. |
Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Revision #3
Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer
Study Coordinator(s) | Raja Mudad, M.D., FACP, Laurie E. Gaspar, M.D., R. Chapman, M.D. |
Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Revision #5
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetacel followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Study Coordinator(s) | Karen Kelly, M.D., Laurie E. Gaspar, M.D., Wilbur A. Franklin, M.D., David R. Gandara, M.D., Paul H. Gumerlock, Ph.D. |
Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, NCCTG, NCIC-CTG, CTSU, EPP |
Revision #3
A Phase II Study of Gemcitabine Plus Irinotecan (CPT-11) In Patients With Esophageal Cancer.
Study Coordinator(s) | Stephen K. Williamson, M.D. |
Participants | Members, NCORP, Medical Oncologists |
Revision #7
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
Study Coordinator(s) | Robert P. Whitehead, M.D. |
Participants | Members, NCORP |
Amendment #2
Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Study Coordinator(s) | Alison T. Stopeck, M.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D., William T. Bellamy, R. Ph. |
Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #2
Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
Study Coordinator(s) | Howard (Jack) West, M.D., Ralph B. Vance, M.D., Wilbur A. Franklin, M.D., Derick H.M. Lau, M.D.,Ph.D., Paul H. Gumerlock, Ph.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists |
Memorandum
A Phase II Trial of STI571 for the Treatment of Platinum and Taxane Refractory Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer
Study Coordinator(s) | Andy Jang, M.D., Sharon Wilczynski, M.D.,Ph.D. |
Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Revision #10
A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB(T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC).
Study Coordinator(s) | Paul A. Bunn Jr., M.D., Katherine M. W. Pisters, M.D., Wilbur A. Franklin, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, Surgeons, CTSU, ECOG, NCCTG, RTOG, ACOSOG, NCIC-CTG |
Revision #6
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach.
Study Coordinator(s) | James H. Doroshow, M.D., John S. Macdonald, M.D. |
Participants | Members, NCORP |
Revision #3
Lung Cancer Specimen Repository Protocol, Ancillary
Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Revision #4
Gastrointestinal Tumor Repository Protocol, Ancillary
Study Coordinator(s) | Cecilia M. Fenoglio-Preiser, M.D., Grant N. Stemmermann, M.D., Amy E. Noffsinger, M.D., Paul E. Hurtubise, M.D. |
Participants | Members, Pathologists, NCORP |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required